ResMed Aktie News

Revenue increased by 9% to $1.3 billion; up 8% on a constant currency basis  Gross margin up 290 bps to 61.5%; non-GAAP gross margin up 280 bps to 62.0% Income from operations increased 15%; non-GAAP income from operations up 19% Diluted earnings per share of $2.37; non-GAAP diluted earnings per share of $2.55 Operating cash flow of $457 million Note: A webcast of Resmed's conference call will ...

SAN DIEGO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2026 on Thursday, October 30, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may al...

ResMed Inc. (NYSE:RMD ) Bank of America Global Healthcare Conference 2025 September 23, 2025 8:20 AM EDT Company Participants Michael Farrell - CEO & Chairman Carlos Nunez - Chief Medical Officer Conference Call Participants Lyanne Harrison - BofA Securities, Research Division Presentation Lyanne Harrison BofA Securities, Research Division Good afternoon, everybody. My name is Lyanne Harrison.

SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the Bank of America Global Healthcare Conference 2025 on Tuesday, September 23, 2025, beginning at approximately 1:20 p.m. (British Summer Time) in London.

I track a universe of 50 high-quality dividend growth stocks to identify attractive investment opportunities based on valuation and future return potential. My custom valuation model highlights 23 stocks with estimated future returns above 10%, with 12 of these also appearing undervalued by free cash flow. Top picks include Resmed, MarketAxess, Ferrari, MSCI, Accenture, and others, each offerin...

New global clinical insights initiative debuts at World Sleep Congress 2025 to help drive innovation in sleep health care New global clinical insights initiative debuts at World Sleep Congress 2025 to help drive innovation in sleep health care

SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced the publication of a landmark study in The Lancet Respiratory Medicine projecting a significant rise in obstructive sleep apnea (OSA) in the United States over the next three decades due to a variety of fact...

For my first rating of ResMed, I'm calling a buy, agreeing with today's consensus from Wall St. and more confident than the quant system, which said hold. Key upside factors are new business acquisitions and FDA approvals, proven demand momentum so far, and revenue diversification along with strong profit margins in its peer group. RMD is a proven dividend grower over 10 years while also having...